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Summary An adolescentmale developed encephalopathy andmultiple organ involvement with
rhabdomyolysis during primary HIV infection (PHI). All symptoms and signs resolved within a few
days. Nineteen cases of central nervous system complications (other than aseptic meningitis)
have been reported in PHI. These include encephalopathy, meningoencephalitis, acute disse-
minated encephalomyelitis, multiple sclerosis, myelopathy, and meningoradiculitis. Half of the
patients died or suffered sequelae. Except in cases of multiple sclerosis, steroids were not of
benefit. Initiation of antiretrovirals during PHI remains controversial. Rhabdomyolysis was
reported in eight patients with PHI. All patients recovered. Primary HIV infection should be
considered when the clinician faces patients with unexplained neurologic manifestations,
rhabdomyolysis, or multiple organ involvement.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Primary HIV infection (PHI) is symptomatic in 50—90% of
cases of seroconversion.1,2 Symptomatic PHI occurs 2—6
weeks after exposure and usually lasts 1—2 weeks.2 Com-
monly reported symptoms and signs include amononucleosis
or influenza-like syndrome with fever, fatigue, pharyngitis,
maculopapular rash, lymphadenopathy, headache, myalgia,
arthralgia, oral or genital ulcers, and gastrointestinal dis-
turbances, in combination or isolated. Laboratory findings
may include leukopenia, lymphopenia, thrombocytopenia,
or atypical lymphocytes. Neurologic manifestations such as
aseptic meningitis, encephalitis, or neuropathies have been* Corresponding author. Tel.: +1 718 7412470; fax: +1 718 6546692.
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doi:10.1016/j.ijid.2009.01.005reported in 17%.1 Twenty-two percent of patients with PHI
may require hospitalization because of neurological symp-
toms.3 To our knowledge this is the first report of a PHI
complicated by acute encephalopathy and multi-organ
involvement with rhabdomyolysis, and it occurred in an
adolescent.
Case report
A 20-year-old previously healthy adolescent male, presented
to our emergency department in March with severe abdom-
inal pain, fever, chills, headache, and watery diarrhea of 8-
day duration. Vomiting and sore throat had started 3 days
previously. Initially he was constipated. There was no history
of arthralgia, weight loss, genital ulcers, penile discharge, or
excessive exercise. He denied alcohol or illicit drug use,Published by Elsevier Ltd. All rights reserved.
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was a college student, living in a dormitory. He was homo-
sexual and reported non-consistent condom use. Two months
previously he had had a negative routine screening test for
HIV, per his report.
On physical examination his blood pressure was 74/38
mmHg, temperature 39.3 8C, heart rate 84 beats/min, and
respiratory rate 22/min. He was oriented and his neck was
supple. He had injected conjunctivae and an erythematous
pharynx without any exudates or ulcers. Two-cm left poster-
ior cervical lymph nodes were palpated. A macular blanching
rash over his chest was noted. His abdomen was diffusely
tender without rebound; bowel sounds were audible. He had
no hepatosplenomegaly or muscle tenderness. The rest of the
examination was unremarkable.
Laboratory values showed: white blood cell count (WBC)
of 1.6  109 cells/l with 61% neutrophils, 5% bands, 28%
lymphocytes, and 6% monocytes; hemoglobin 13.2 g/dl,
hematocrit 29%, and platelet count 99  109 cells/l; creati-
nine phosphokinase (CPK) 471 U/l (normal <200), amylase
292 U/l (normal <100), with normal lipase, and C-reactive
protein at 1.2 mg/dl (normal <0.5). The initial working
diagnoses included typhoid fever, mononucleosis-like syn-
drome including acute HIV, and acute abdomen.
On the sixth day of the admission he developed confusion
with prosopagnosia of his parents, irritability, and inconti-
nence. He had fever of 38.1 8C and normal blood pressure. A
limited neurologic examination because of lack of coopera-
tion did not disclose any focal deficits. Laboratory tests
detected increased CPK at 2968 U/l, lactate dehydrogenase
(LDH) at 1323 U/l (normal<190), aspartate aminotransferase
(AST) at 266 U/l (normal <48), alanine aminotransferase
(ALT) at 254 U/l (normal <40), g-glutamyltranspeptidase
(GGT) at 189 U/l (normal <54), and creatinine at 1.6 mg/
dl. Urinalysis detected grade 4+ blood on dipstick, with 2 red
blood cells (RBC)/high-power field on microscopic examina-
tion. Free thyroxine (T4), thyroid-stimulating hormone
(TSH), serum cortisol, and troponin-T were within normal
limits.
A computed tomography (CT) scan with contrast and
magnetic resonance imaging (MRI) of the brain with contrast
were normal. An electroencephalogram (EEG) showed gen-
eralized continuous polymorphic slowing with delta and
theta waves consistent with diffuse cerebral dysfunction,
worse in the left hemisphere and no seizures. An electro-
cardiogram showed a first-degree heart block and non-spe-
cific STand T-wave changes. An echocardiogram was normal.
Lumbar puncture showed 2  106 lymphocytes/l,
4000  106 RBC/l, protein 150 mg/dl, and glucose 62 mg/
dl. Bacterial and mycobacterial cerebrospinal fluid (CSF)
cultures remained negative. DNA by PCR for herpes simplex
virus (LightCycler, Roche Diagnostics) and cytomegalovirus
(CMV) (TaqMan 7100, Applied Biosystems) and cryptococcal
antigen were not detected in the CSF. During his hospitaliza-
tion a nasal influenza antigen test and throat, blood, and
urine cultures were negative for bacteria. Serologies were
consistent with past infection for CMV, Epstein—Barr virus,
and parvovirus B19, past immunization for hepatitis B, and
negative for toxoplasma, syphilis, hepatitis A and C, and
cryptococcal antigen. An HIV antibody test by ELISA was
non-reactive. The plasma HIV RNA level was >500 000
copies/ml (System 340 bDNA analyzer, Siemens). The CD4+T-lymphocyte count was 140 cells/ml (28%) (normal range
395—1495/ml, 32—64%).
The encephalopathy, rhabdomyolysis, hepatitis, and the
clinical symptoms completely resolved 12 days after admis-
sion. The electrocardiographic abnormalities persisted. He
received empiric treatment with ceftriaxone, vancomycin
and acyclovir for a few days, until the diagnosis of primary
HIV infection was made and other tests returned negative.
Four months later his viral loadwas 133 563 copies/ml and the
CD4+ T-cell count 368/ml (23%) without having started highly
active anti-retroviral treatment (HAART).
Discussion
It is estimated that 15% of the 35 000 new HIV infections in 33
states each year occur in people aged 13—24 years.4 PHI is
characterized by detectable HIV-RNA or p24 antigen with
negative or inconclusive serology, or seroconversion within
the last 6—12 months.5,6 These criteria were used to identify
reported cases of PHI with central nervous system (CNS)
involvement, not including cases of aseptic meningitis.
Self-limited aseptic meningitis was reported in 10/41 (24%)
patients with PHI.6
The terms ‘primary or acute HIV or HTLV-III’ and ‘neuro-
logic complications or encephalopathy’ were used to search
the Medline/PubMed database for the period 1983 to Sep-
tember 2008. Nineteen cases of CNS complications, excluding
aseptic meningitis, that occurred during PHI were found in
the English literature (Table 1).7—24
These included cases of encephalopathy, encephalitis,
meningoencephalitis, acute disseminated encephalomyelo-
pathy, multiple sclerosis, meningoradiculitis, myelopathy,
and cauda equina syndrome. The median age was 31 years
(range 20—55). The male to female ratio was 2.1:1.
Symptoms consistent with acute retroviral syndrome were
described in 14/19 cases (74%). Rash was reported in 6/19
(32%) cases and was usually described as transient maculo-
papular erythematous lesions, more prominent over the
torso.8,9,12,13,14,22 Mouth ulcers occurred in four
cases8,16,22,24 and splenomegaly in one.22
Fourteen cases of encephalopathy, encephalitis, or
meningoencephalitis that occurred during PHI were identi-
fied.7—19 Mental status changes were reported in 11/14 (79%),
coma in two (14%), fever in 12 (86%), seizures in four (29%),
ataxia in three (21%), and nuchal rigidity in two (14%).
Localized neurologic symptoms and signs such as diplopia,
nystagmus,11 visual field defect,12 bilateral facial nerve
palsy, hemiplegia,18 motor-sensory neuropathies of the
extremities,9 and Babinski reflex7,18 were reported in single
patients.
The CSF WBC count was elevated in 15/18 (83%) of all the
cases in which lumbar puncture results were available (med-
ian value 100  106/l, range 6—633  106/l). Lymphocytes or
monocytes were predominant. CSF protein was elevated in
10/15 (67%) cases (median value 114.5 mg/dl, range 62—
1082 mg/dl) and glucose was normal.
Transaminases were increased in five cases,8,9,14,22,23 and
spontaneously resolving leukopenia, lymphopenia, and/or
thrombocytopenia were commonly reported. The CD4 T-cell
count was decreased (<395 cells/ml) in 3/8 cases.
MRI and/or CTscan of the CNS was abnormal in 7/13 (54%)
cases. In cases of encephalopathy, encephalitis, or menin-
Table 1 CNS manifestations during primary HIV infectiona
Case/age/sex/ Ref. Clinical diagnosis MRI/CT brain CSF Serum Treatment Duration Sequelae
WBC count
(106/l)
Protein
(mg/dl)
Glucose
(mg/dl)
Viral copies
(103/ml)
HIV
Ag
Viral copies
(106/ml)
HIV
Ag
Anti-
HIV
CD4 count
(/ml)
1/20y/M 7 Encephalopathy  3 91 70 NA NA NA NA + NA NS 12 h None
2/55y/M 7 Encephalopathy + 0 Normal Normal NA NA NA NA + NA NS 1—3 m None
3/35y/M 8 Encephalopathy NA 22 Normal Normal NA NA NA NA + NA NS 2—3 wk None
4/53y/M 9 Encephalopathy,
neuropathy
 100 40 NA NA NA NA NA + 465 NS Brief Dysesthesia
of legs
5/27y/M 10 Encephalopathy NA Normal NA NA NA NA NA +  NA NS 14 d None
6/31y/F 11 Leukoencephalopathy + 485 106 66 NA p24 NA   NA DXM 5 d Died
7/31y/M 12 Encephalopathy NA 10 69 61 NA NA 3.6 p24  410 NS 8 d None
8/31y/M 13 Encephalopathy,
coma
+ 217 NA NA >500 NA >0.5 NA  621 Lopinavir,
efavirenz,
AZT, DXM
11 d Died
9/30y/M 14 Encephalopathy,
coma
NA 633 NA NA 4840 NA 0.55 NA + 44 AZT,
abacavir,
lamivudine
48 h None
10/26y/M 15 Encephalitis  12 1082 Normal NA NA NA NA + 484 NS 2 d Cognitive
impairment
11/47y/F 16 Encephalitis, ataxia  107 140 NA NA + NA + + NA DXM 2—3 wk None
12/26y/M 17 Meningoencephalitis  52 180 75 +  NA   140 NS 6 d None
13/42y/M 18 Cerebral angiitis + 329 123 85 NA + NA   NA PDN, CYCL 4 m Died
14/27y/F 19 Acute disseminated
encephalomyelitis
+ 512 130 55 86 NA 29 p24  200 Steroids,
IVIG, AZT,
lamivudine,
indinavir
10 d Visual,
paraplegia,
bladder
dysfunction
15/33y/M 20 Multiple sclerosis + NA NA NA NA NA + NA + NA DXM, PDN,
AZT
1—2 m Hemiparesis
16/28y/F 21 Multiple sclerosis + 6 Normal Normal NA NA NA NA + NA Steroids,
plasmapheresis
5 y Recurrent
17/29y/M 22 Myelopathy  7 65 59 NA NA NA NA + NA NS 2 m Paraparesis
18/40y/F 23 Meningoradiculitis NA 105 62 NA NA NA + +  Normal NS 3 wk None
19/36y/F 24 Cauda equina NA 10 26 NA NA NA NA +  NA AZT 5 m Improved
Present case Encephalopathy  2 150 62 NA NA >0.5 NA  140 NS 3 d None
CNS, central nervous system; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; CT, computed tomography; WBC, white blood cell; Ag, antigen; NA, not available; NS, non-specific; +,
detected or represents seroconversion if other markers of infection are negative; , equivocal; , negative; AZT, azidothymidine; CYCL, cyclophosphamide; DXM, dexamethasone; IVIG,
intravenous immunoglobulin; PDN, prednisone; y, years; m, months; wk, weeks; d, days.
a Cases of aseptic meningitis are not included.
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e302 M. Douvoyiannis, N. Litmangoencephalitis, lesions were found in 5/10 (50%) cases. Four
out of these five patients suffered sequelae or died, as
opposed to 2/5 of those without radiographic lesions. One
patient who died had diffuse hyperintense lesions in the
cortex on MRI.13 Cerebral angiography showed diffuse nar-
rowing of medium and large-size vessels in a patient with
cerebral angiitis.18 EEG was abnormal in all eight cases of
encephalopathy/encephalitis or meningoencephalitis in
which it was performed. Diffuse, as in our patient, or bi-
temporal slow-wave activity was the usual finding.
Brain biopsy in two cases of multiple sclerosis and in a case
of leukoencephalopathy, showed demyelination.11,20,21 In a
case of cerebral angiitis, infarcts in the basal ganglia, white
and gray matter were found.18 HIV by in situ hybridization,
or by culture or HIV antigen, were detected in the brain
tissue.11,18,20
In patients with encephalopathy/encephalitis or menin-
goencephalitis, 4/5 who received steroids versus 2/9 who did
not receive steroids died or suffered sequelae. This may just
reflect that steroids were more commonly used in more
critical cases. Steroids and plasmapheresis were helpful in
cases of multiple sclerosis.20,21
HAART was administered in two patients with encephalo-
pathy with different outcomes. One died in 11 days and the
other recovered in 48 h.13,14 In a patient with acute dissemi-
nated encephalomyelitis, clinical, radiologic and immunologic
improvement occurred 10 days after HAART administration,
while intravenous immunoglobulin and steroids had previously
failed.19 A patient with cauda equina syndrome improved 5
months after zidovudine administration.24
In 9/19 (47%) cases the neurologic complications comple-
tely resolved. Three (16%) patients died and seven (37%)
suffered sequelae. Encephalopathy/encephalitis or menin-
goencephalitis usually lasted a few days (range 12 h to 4
months).
Concurrent presentation of encephalopathy or other CNS
manifestations with rhabdomyolysis in PHI, as in our patient,
has not been previously described. Acute rhabdomyolysis has
been reported in the later stages of HIV infection. In PHI it has
been described in eight cases and resolved within a few
days.25—32 Muscle tenderness was a common finding. The
median elevation of the CPK was 6802 U/l (range 2734—
63 000). Both AST and ALT were elevated in five cases.
Rhabdomyolysis occurred concurrently with renal failure,25
myocarditis,27,32 and liver failure,32 or without any other
symptoms suggestive of PHI.31 As myalgias may occur in up to
70% during PHI, the incidence of rhabdomyolysis is probably
underestimated.30
Although in our patient the degree of CPK elevation was
mild, caution is needed in such cases, as rhabdomyolysis
may further complicate the neurologic disease by causing
renal failure, electrolyte abnormalities and subsequent
hypertension.
Whether the patients with rhabdomyolysis during PHI have
an increased susceptibility to myopathy or rhabdomyolysis
caused by medications such as zidovudine, lamivudine, rito-
navir and indinavir, or statins, or have an increased risk to
recurrent rhabdomyolysis, or to HIV-polymyositis associated
with immune restoration inflammatory syndrome needs to be
further studied.
Direct viral toxicity and/or immune mediated toxicity are
thought to be involved in the development of the acute retro-viral syndrome.5 In addition HIV stimulates cytotoxic T-lym-
phocyte responses that may contribute to the brain injury.33
CSF viral load was higher in patients with PHI who had
neurologic complications.3 No correlation was found
between plasma viral load and neurologic involvement. Con-
versely HIV virus or antibodies against HIV have been
detected in the CSF in asymptomatic seropositive patients.34
The finding of specific antibodies in the CSF is not diagnostic
of a neurologic disease caused by the HIV, unless other ill-
nesses such as opportunistic infections or neoplasms have
been excluded.35
Similarly, immune mediated toxicity or direct viral toxi-
city within the muscles have been proposed as underlying
mechanisms of rhabdomyolysis. Invasion by CD8+ cytotoxic T
cells forming complexes with major histocompatibility com-
plex I (MHC I) that are aberrantly expressed by myofibers is a
characteristic finding of HIV-associated myopathy.36 HIV gen-
ome and antigens have been detected in macrophages and
lymphocytes surrounding the muscle fibers but not in the
muscle fiber itself, with the exception of one study.37 These
findings are more suggestive of an autoimmune process than
direct viral toxicity as a cause of muscle injury and rhabdo-
myolysis in PHI.
Regarding treatment, the role of HAART in PHI remains
controversial.38 The occurrence of neurologic involvement in
PHI has been associated with increased risk for disease
progression1 and can be severe, even leading to death.13
HAART in PHI has been associated with resolution of the
clinical symptoms, virologic and immunologic benefits,
decrease of minor opportunistic infections, and delay of
progression to AIDS.39,40 In a single trial, initiation of HAART
within 6 months of seroconversion was associated with
decreased viral load and improved CD4 count for more than
6 months, after termination of an at least 12 weeks course.
These immunologic benefits persisted for up to 18 months if
HAART was started within the first 2 weeks of seroconver-
sion.41 Nevertheless the authors suggested that these data be
interpreted with caution as the benefits of early treatment
might have been overestimated by the analysis, as there was
a lack of statistical significance at 18 months and the sample
size was small. Results from the Concerted Action on Ser-
oConversion to AIDS and Death in Europe (CASCADE) cohort of
seroconverters, suggested that limited CD4 cell gains may
result only when HAART is administered for longer than 1
year, but further data were needed.42 Other studies have not
demonstrated a sustained benefit of early initiation of HAART
on CD4 cell count and viral load after treatment was dis-
continued.43,44
Arguments against the initiation of HAART during PHI
also include drug toxicity and the risk of development of
viral resistance. The last may be an important issue espe-
cially in adolescence, because of inadequate adherence to
treatment. Penetration of the antiretrovirals into the CSF
should be taken into account when choosing the appropri-
ate regimen.
Conclusions
Up to three quarters of symptomatic PHI may bemissed at the
first medical visit.6 The clinical picture includes, beyond the
mononucleosis-like symptoms, rhabdomyolysis and neurolo-
gic complications ranging from headache to encephalopathy.
Primary HIV with encephalopathy and rhabdomyolysis e303Traditional risk factors for HIV infection may be absent or not
perceived as such or initially not disclosed and serology may
be negative. A high index of suspicion, which includes a
thorough history and assays to detect viral load, is required
for the diagnosis of PHI. Timely diagnosis also has major
implications in counseling about transmission prevention,
in particular because during the acute infection the viral
load and the risk of transmission is very high.41 To address the
issues of optimal time of initiation, duration and long-term
benefits of early HAART in PHI, randomized clinical trials are
needed, such as the Short Pulse HIV Anti-Retroviral Treat-
ment at SeroConversion (SPARTAC) trial, which is underway.
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